DISCOUNT OPTIONSSCHEIN - NOVO NORDISK ADR B | Real-time Boerse Frankfurt Warrants 12:40:42 24/06/2024 BST | ||
| 0.72 EUR | +1.41% |
|
| Current month | -15.48% | ||
| 1 month | -14.46% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 24/06/24 | 0.72 | +1.41% |
| 21/06/24 | 0.71 | -2.74% |
| 20/06/24 | 0.73 | +1.39% |
| 19/06/24 | 0.72 | -2.70% |
| 18/06/24 | 0.74 | +1.37% |
Real-time Boerse Frankfurt Warrants
Last update June 24, 2024 at 12:40 pm
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | PUT |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Vontobel
|
| WKN | VD3WR5 |
| ISIN | DE000VD3WR54 |
| Date issued | 10/04/2024 |
| Strike | 140 $ |
| Maturity | 21/03/2025 (270 Days) |
| Parity | 10 : 1 |
| Emission price | 0.95 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.13 € |
|---|---|
| Lowest since issue | 0.66 € |
| Spread | 0.01 € |
| Spread % | 1.37% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
987.9
DKK
Average target price
934.3
DKK
Spread / Average Target
-5.43%
- Stock Market
- Certificates
- Certificat
